TY - JOUR
T1 - Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
AU - Asakawa, Masahiro
AU - Mitsui, Hiroshi
AU - Akihisa, Momoko
AU - Sekine, Tetsuo
AU - Niitsu, Yoshihiro
AU - Kobayashi, Arisa
AU - Miyake, Atsuko
AU - Hashimoto, Naoaki
AU - Kawamura, Mitsunobu
AU - Ogawa, Yoshihiro
N1 - Publisher Copyright:
© 2015, Asakawa et al.
PY - 2015/12/28
Y1 - 2015/12/28
N2 - Aim: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. Methods: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated. Results: HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes. Conclusion: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis.
AB - Aim: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. Methods: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated. Results: HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes. Conclusion: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis.
UR - http://www.scopus.com/inward/record.url?scp=84938062884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938062884&partnerID=8YFLogxK
U2 - 10.1186/s40064-015-1135-z
DO - 10.1186/s40064-015-1135-z
M3 - Article
AN - SCOPUS:84938062884
SN - 2193-1801
VL - 4
JO - SpringerPlus
JF - SpringerPlus
IS - 1
M1 - 346
ER -
